Dadachanji Group Reenters Pharmaceutical Glass Packaging Market with Kaisha Pharma
The Dadachanji Group has reentered the pharmaceutical glass packaging sector through its new venture, Kaisha Pharma. This marks a return to an industry it had exited in 2021 when Serum Institute of India acquired Schott Kaisha's Indian partner stake. The group is investing €45 million ($52.2 million) initially to expand production capacity and adopt a more global strategy compared to its previous India-focused operations. Kaisha Pharma will offer products such as tubular glass ampoules, vials, prefilled syringes, and cartridges with ready-to-use platforms for these items. The group also launched Kairish Innotech earlier this year to provide secondary deep-tech architecture including medical device design, robotics, sterilization, and automation. Rishad Dadachanji emphasized the goal of removing limitations in adapting standard equipment through innovation from concept to fully functional machines on clients' floors.
Topics: Corporate Strategy Glass Manufacturing Pharmaceutical Packaging